CA3217092A1 - Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors - Google Patents

Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors Download PDF

Info

Publication number
CA3217092A1
CA3217092A1 CA3217092A CA3217092A CA3217092A1 CA 3217092 A1 CA3217092 A1 CA 3217092A1 CA 3217092 A CA3217092 A CA 3217092A CA 3217092 A CA3217092 A CA 3217092A CA 3217092 A1 CA3217092 A1 CA 3217092A1
Authority
CA
Canada
Prior art keywords
cio
egfr
inhibitor
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3217092A
Other languages
English (en)
French (fr)
Inventor
Farbod Shojaei
Jill M. RICONO
Robert Goodenow
Mireille GILLINGS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huyabio International LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3217092A1 publication Critical patent/CA3217092A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3217092A 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors Pending CA3217092A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184697P 2021-05-05 2021-05-05
US63/184,697 2021-05-05
US202263320991P 2022-03-17 2022-03-17
US63/320,991 2022-03-17
PCT/US2022/027693 WO2022235815A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3217092A1 true CA3217092A1 (en) 2022-11-10

Family

ID=83932546

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3217092A Pending CA3217092A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Country Status (8)

Country Link
US (1) US20220370456A1 (https=)
EP (1) EP4334317A4 (https=)
JP (1) JP2024516998A (https=)
AU (1) AU2022270106A1 (https=)
CA (1) CA3217092A1 (https=)
IL (1) IL308225A (https=)
MX (1) MX2023012929A (https=)
WO (1) WO2022235815A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216706A1 (en) * 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CA3048340A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
US11033547B2 (en) * 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
JP2024505680A (ja) * 2021-02-05 2024-02-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
IL308222A (en) * 2021-05-05 2024-01-01 Huyabio Int Llc Combination therapies that include SHP2 inhibitors and PD-1 inhibitors
JP2024516997A (ja) * 2021-05-05 2024-04-18 フヤバイオ インターナショナル，エルエルシー Ｓｈｐ２阻害剤単独療法およびその使用

Also Published As

Publication number Publication date
JP2024516998A (ja) 2024-04-18
IL308225A (en) 2024-01-01
WO2022235815A1 (en) 2022-11-10
EP4334317A1 (en) 2024-03-13
EP4334317A4 (en) 2025-03-05
AU2022270106A1 (en) 2023-12-14
MX2023012929A (es) 2023-11-13
US20220370456A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
US12390469B2 (en) SHP2 inhibitor monotherapy and uses thereof
CN107922431B (zh) Hpk1抑制剂及其使用方法
US20100104567A1 (en) Pharmaceutical composition
EA032509B1 (ru) Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
TW201819380A (zh) 作為抗病毒劑之稠合四環吡啶酮化合物
PH12014501626B1 (en) Therapeutically active compounds and their methods of use
WO2017146236A1 (ja) Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
JP2023548204A (ja) Ｃｄ７３阻害剤及びその応用
JP2019048822A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
US12097203B2 (en) Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
JP2021512103A (ja) Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
US20230293539A1 (en) Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
TW202539662A (zh) 抗腫瘤組合物
CA3217092A1 (en) Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors
CN117677619A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
CN117642398A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
HK40108830A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
HK40108828A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
ES2956866T3 (es) Inmunomoduladores heterocíclicos como inhibidor del punto de control del pdl1
US20230097801A1 (en) Methods of increasing cell phagocytosis
HK40108829A (zh) Shp2抑制剂单一疗法及其用途
JP2020520378A (ja) アスコクロリン誘導体を用いた併用療法
KR20230072446A (ko) 암의 치료를 위한 인돌아민 2,3-디옥시게나아제 저해제와 면역체크포인트 억제제의 상승적 조합
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine
TW201938149A (zh) 用於治療癌症的選擇性組蛋白去乙醯酶3 (hdac3)抑制劑及免疫治療劑之組合

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425